Mycobacterial infections in solid organ transplant recipients  by Meije, Y. et al.
Mycobacterial infections in solid organ transplant recipients
Y. Meije1, C. Piersimoni2, J. Torre-Cisneros3, A. G. Dilektasli4 and J. M. Aguado5, on behalf of the ESCMID Study Group of
Infection in Compromised Hosts (ESGICH)
1) Infectious Diseases Department, Hospital Universitari Vall d0Hebron, Barcelona, Spain, 2) Regional Reference Mycobacteria Laboratory, Azienda Ospedaliera
Universitaria Ospedali Riuniti, Ancona, Italy, 3) Instituto Maimonides de Investigacion Biomedica de Cordoba (IMIBIC), Hospital Universitario Reina Sofıa,
Universidad de Cordoba, Cordoba, Spain, 4) Department of Pulmonary Diseases, Uludag University School of Medicine, Bursa, Turkey and 5) Infectious Diseases
Department, Hospital Universitario 12 de Octubre, Madrid, Spain
Abstract
Mycobacterial infections represent a growing challenge for solid organ transplant recipients (SOT). The adverse effects of tuberculosis (TB)
therapy present a major difﬁculty, due to the interactions with immunosuppressive drugs and direct drug toxicity. While TB may be
donor-transmitted or community-acquired, it usually develops at a latent infection site in the recipient. Pre-transplant prevention efforts will
improve transplant outcomes and avoid the complications associated with post-transplant diagnosis and treatment. The present review and
consensus manuscript is based on the updated published information and expert recommendations. The current data about epidemiology,
diagnosis, new regimens for the treatment of latent TB infection (LTBI), the experience with rifamycins for the treatment of active TB in the
post-transplant period and the experience with isoniazid for LTBI in the liver transplant population, are also reviewed. We attempt to
provide useful recommendations for each transplant period and problem concerning mycobacterial infections in SOT recipients.
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Hot Topics
 Because active tuberculosis (TB) is associated with high
mortality in solid organ transplant (SOT) recipients, all
transplant candidates should undergo evaluation for latent
TB infection (LTBI) AII.
 The tuberculin skin test (TST) is currently the standard
method for identifying subjects at risk. The TST is consid-
ered positive if there is ≥5 mm of induration at 48–72 h (AI).
 Whenever possible, patients with either positive or negative
TST results should undergo an IGRA test interpreted
according to the manufacturer’s instructions (BIII).
 Before initiation of treatment for LTBI, patients with positive
immunological test results (TST and/or IGRA) should be
evaluated so as to rule out active TB (AI).
 A diagnosis of TB can only be conﬁrmed by culturing
MTC or by identifying speciﬁc nucleic acid sequences in a
clinical specimen collected from the suspected site of
disease AII.
 Treatment for LTBI should be administered to patients on
transplant waiting lists or to recipients after transplantation
who have ≥1 of the following conditions: (i) a TST (initial or
after a booster effect) with a 5-mm induration or positive
IGRA result; (ii) a history of untreated TB; or (iii) a history of
contact with a patient with active TB (AII).
 The drug of choice for LTBI is isoniazid (300 mg/day)
supplemented with vitamin B6 for 9 months (AI).
 For localized, non-severe forms of TB and periods with high
rejection rates, it may be advisable to avoid the use of
rifamycins (B-II). Maintenance therapy with isoniazid and
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ethambutol (or pyrazinamide) is recommended for 12–
18 months (CIII).
 For severe forms or disseminated TB, the use of a TB regimen
that includes rifampicin or rifabutin should be considered
(B-II). Maintenance therapy with isoniazid and rifampicin or
rifabutin is recommended for at least 9 months (BIII).
Introduction
Tuberculosis (TB) represents a growing challenge for SOT
recipients, as it is associated with high transplant failure and
mortality rates.
The epidemiology of TB in a country determines the risk of
developing TB disease after transplantation, compounded by
the increased risk among SOT recipients compared with the
general population in a given area [1,2]. In addition, variability
in the risk of TB is accounted for by centre-related differences
in the management of LTBI and active TB [3].
The heterogeneity of TB epidemiology in Europe is high.
The incidence of TB ranges from <20 to >75 per 100 000
people according to country and multidrug-resistant rates [4–
7]. Few studies have adequately described the incidence rate in
the transplantation setting. The incidence of TB in SOT
recipients in Europe has previously been reported to be as high
as 3.5% [8] although large current series suggest a lower rate
(0.45–0.9%), [2,9,10]. The highest incidence (6.4–10%) is
observed in lung transplant recipients [11–13].
Tuberculosis-related mortality in SOT recipients has been
reported to be as high as 40% [14,15]. Although this mortality
rate may have decreased due to better diagnostic techniques,
it remains high (9.5–17%) [2,10]. In addition, there are no
reports of the mortality rate in Eastern European countries,
where the prevalence of TB is high.
Although the majority of patients develop pulmonary TB,
the percentage of SOT recipients who develop extrapulmo-
nary or disseminated TB is higher than in the general
population [9,15–17]. Immune reconstitution and haemo-phag-
ocytic syndrome associated with TB have also been reported
in SOT recipients [9,18]. Most patients develop TB infection in
the ﬁrst year post-transplantation [2] but a bi-modal distribu-
tion has also been observed, with the incidence of TB at a peak
2 years after SOT [1,17].
The adverse effects of TB therapy present a major difﬁculty,
due to the interactions with immunosuppressive drugs and
direct drug toxicity. The current rise in drug resistance in the
Mycobacterium tuberculosis complex (MTC) makes TB therapy
even more challenging in some European areas.
While TB may be donor transmitted or community
acquired, it usually develops at a latent infection site in the
recipient, especially in Western Europe, where its prevalence
is low [9,19]. Pre-transplant prevention efforts will improve
transplant outcomes and avoid the complications associated
with post-transplant diagnosis and treatment.
Diagnosis
Latent tuberculosis infection
Latent TB infection is deﬁned as infection with MTC at an
early stage with a viable organism in a dormant state.
Although the diagnosis of LTBI is hampered by the lack of a
reference standard, it is usually made by documenting a
positive TST in a person who has no signs, symptoms or
chest radiograph evidence of active TB disease [20]. Unfor-
tunately, TST often gives false-negative results in anergic
patients, such as those receiving immunosuppressive thera-
pies and/or affected by chronic kidney and liver disease. It
may also give false-positive results in areas in which BCG
vaccination is prevalent or when there is accidental exposure
to environmental non-tuberculous mycobacteria (NTM).
Novel blood tests have become available which detect
gamma interferon production in response to antigens
encoded by the RD-1 region of the MTC genome. These
tests, now known as IGRAs (interferon gamma release
assays), seem to be more speciﬁc (presenting no cross-reac-
tivity with BCG and NTM) and less affected by immunosup-
pressive therapies, despite undergoing the same inhibition of
immune mechanisms that is responsible for the impaired
performance of TST.
Two commercially produced IGRAs are available, the Quan-
tiFERON-TB Gold test (QFT-G; Cellestis Limited, Carnegie,
Victoria, Australia), later replaced by the QuantiFERON-TB
Gold In-Tube test (QFT-GIT; Cellestis), and the T-SPOT.TB
(T-SPOT; Oxford Immunotec, Abingdon, UK). Both tests
employ a mitogen-induced positive control able to differentiate
between an anergic and a true negative response. With both
tests, theresultmaybereportedasqualitative (positive/negative)
or quantitative according to deﬁned cut-off values. Quantitative
results seem more accurate in detecting the progression of TB
infection. While the QFT-GIT test is technically easier to
perform and is widely used in clinical laboratories, recent
evidence suggests that the T-SPOT, less prone to indeterminate
results, is the more sensitive and speciﬁc of the two tests,
especially in immunosuppressed patients [21–24].
QFT-GIT presented higher positivity than TST and provided
a more accurate reﬂection of the risk of LTBI among kidney
transplant candidates [25]. QFT-GIT also showed a role in
predicting subsequent TB development in kidney transplant
recipients in whom TST did not detect LTBI [26]. In patients
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awaiting liver transplantation, TST and QFT-G were compa-
rable for the diagnosis of LTBI, presenting a reasonable
concordance between tests [27]. Indeterminate results were
more likely in patients with advanced liver disease, using either
QFT-G or QFT-GIT [27–29].
As TB is a very serious complication in SOT recipients and
both TST and IGRAs may have false-positive and negative
results, their concurrent use would be the ideal approach for
increasing diagnostic sensitivity [24]. However, this is not
always feasible, either for ﬁnancial reasons or due to the
characteristics of speciﬁc centres. In our view, excellence not
only means transferring new scientiﬁc data into daily practice,
but, above all, carrying out ordinary tasks to perfection. In
everyday practice, many patients undergo transplantation
without a prior TST [30]. The scarcity of data in the transplant
population and the lack of a reference standard make any
deﬁnite recommendation difﬁcult.
In addition, when transplants are carried out from deceased
donors in whom laboratory investigations cannot be performed,
TB transmission may represent an under-appreciated risk [31].
The value of IGRAs in this situation needs further investigation,
particularly in lung transplantation [30].
Recommendations for diagnosing latent tuberculosis
infection
 Because active TB is associated with a high mortality rate in
SOT recipients, all transplant candidates should undergo
evaluation for LTBI (AII).
 TST is currently the standard method for identifying subjects
at risk; a test is considered positive if there is ≥5 mm of
induration at 48–72 h (AI).
 Patients with either positive or negative TST results should
undergo an IGRA test interpreted according to the manu-
facturer’s instructions [32] (BIII).
 In the case of discrepant results, any positivity (unless
related to a documented BCG vaccination) should be
considered for the treatment of LTBI [32,33] (BIII).
 Before initiation of treatment of LTBI, patients with positive
immunological test results (TST and/or IGRA) should be
evaluated in order to rule out active TB (AI).
 Should IGRA tests be unavailable, a second TST (7–10 days
after the ﬁrst test) should be performed in patients with a
negative reaction, in search of a boosting-related skin
conversion (AIII).
 Living donors should undergo the same evaluation as
transplant recipient candidates [34] (AII).
 When neither TST nor IGRA testing can be performed, as in
the case of deceased donors, a history should be obtained
from the donor’s family of previous latent or active TB and
any associated treatment [34] (AII).
Active tuberculosis
Active TB after solid organ transplantation may present at any
time during the post-transplant period and is associated with
extensive morbidity and mortality [35]. Because of its
non-speciﬁc clinical manifestations, the lack of clear symptoms
and in some cases the presence of extrapulmonary involve-
ment, diagnosis may be problematic [18,36]. In addition,
patients may often have coexistent infections and non-infec-
tious complications that add new challenges to the diagnosis.
Therefore, a high index of suspicion is of utmost importance
for performing an appropriate diagnostic workup. Invasive
procedures may be necessary to obtain specimens from the
body sites most likely to yield mycobacteria [20].
Recommendations for diagnosing active tuberculosis
 A diagnosis of TB can only be conﬁrmed by culturing MTC
or by identifying speciﬁc nucleic acid sequences in a clinical
specimen collected from the suspected site of disease (AII).
 Culture is the most sensitive detection method; growth is
necessary for deﬁnitive species identiﬁcation and full drug
susceptibility testing (DST) [37] (AII).
 Today, a combination of liquid and solid culture gives the
fastest and most accurate rates of mycobacterial recovery
from clinical specimens [38] (AII).
 Smears for acid-fast bacilli (AFB) and mycobacterial culture
should be required whenever TB is suspected (AII).
 In the case of pulmonary disease, invasive techniques such as
bronchoscopy with bronchoalveolar lavage, transbronchial
biopsy and/or mediastinoscopy should be performed as soon
as routine sputumexamination is found tobeuninformative (AII).
 For extrapulmonary TB, a diagnostic approach aiming to
obtain direct sampling from the involved site is recom-
mended (Table 1) (AII).
 If an unexplained fever raises the suspicion of disseminated
disease,mycobacterialbloodculturesshouldbeobtained(BIII).
 Ampliﬁcation tests performed on respiratory and/or extra-
pulmonary specimens are required to conﬁrm clinical
diagnosis, but do not rule it out [39] (AII).
 When multidrug resistance (MDR) is suspected in a
smear-positive patient, rapid molecular tests able to detect
gene mutation(s) associated with drug resistance in MTC
may be used [40] (BIII).
 Although TST and IGRAs are the cornerstone of the
evaluation of MTC infection, they are complementary tests
in the case of active TB and may be helpful only if positive
(and especially if newly positive) [21] (AII).
 Surveillance cultures performed at ﬁxed times during the
post-transplantation period regardless of any clinical and/or
radiological evidence produce very low yields and should be
discouraged (DIII).
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Prevention (Treatment of Latent
Tuberculosis Infection)
Pre-transplant
Treatment of latent TB infection (LTBI) should only be
considered once active TB has been ruled out. Therefore, if
clinical or radiological data suggest TB, sputa and/or other
respiratory specimens (bronchoaspirate, BAL) must be col-
lected to preclude active disease before initiating LTBI
treatment [36]. This is even more important for lung
transplant recipients in whom a high incidence of explant-asso-
ciated TB has been documented [11].
The treatment of LTBI should start before transplanta-
tion. If it cannot be completed before the procedure, it
should be continued afterwards. It should be provided to all
patients on the waiting list for SOT who have ≥1 of the
following conditions: [1] a TST (initial or after a booster
effect) with an induration ≥5 mm and/or a positive IGRA;
[2] a history of untreated TB or chest radiograph ﬁndings
compatible with untreated TB (apical ﬁbronodular lesions,
calciﬁed solitary nodule, calciﬁed lymph nodes, or pleural
thickening), especially in geographical areas such as Europe
where endemic mycoses mimicking TB lesions do not occur;
and/or [3] a history of contact with a patient with active TB
[36,41,42].
The drug of choice for LTBI in the transplant recipient is
isoniazid (300 mg/day), supplemented with vitamin B6, for
9 months [15,42,43]. Prophylaxis with isoniazid has been
shown to prevent TB in randomized studies involving kidney
recipients, both pre-transplant [44,45] and post-transplant
[46,47]. A recent meta-analysis supported the value of
isoniazid as a prophylaxis against TB in renal transplant
recipients at risk of active infection in endemic areas [48].
Tolerance of isoniazid is generally good [49] with few
reported complications [45]. However, isoniazid-induced
hepatotoxicity is possible in these patients. Baseline hepatic
measurements of serum aspartate aminotransferase (AST),
alanine aminotransferase (ALT) and bilirubin levels should be
recorded in all patients. Follow-up evaluations should be
performed at least monthly and patients should be informed
of the possibility of adverse effects [50]. Treatment of LTBI
should be suspended if AST or ALT values increase
three-fold in patients with symptoms or ﬁve-fold in patients
without accompanying symptoms [42,51]. A liver biopsy is
only recommended when diagnosis is doubtful or when
laboratory values do not return to normal after treatment
withdrawal.
When suspension of LTBI treatment is necessary, patients
should be closely monitored. Treatment should be completed
with drugs other than isoniazid in high-risk patients, such as
those whose TST and/or IGRA results have changed from
negative to positive or some lung transplant patients for whom
high risk factors should be individualized. For patients at high risk
of TB and isoniazid toxicity, we recommend treatment with
levoﬂoxacin (or moxiﬂoxacin) for at least 6 months. However,
there are no controlled trials that support this treatment [36].
Other prophylactic alternatives, for which only limited data
are available in the SOT population, include isoniazid given
twice weekly by directly observed therapy (DOT), rifampicin
(with or without isoniazid) for 4 months [42,52,53] and weekly
rifapentine and isoniazid for 3 months as DOT [54,55]. These
latter alternatives have the beneﬁt of a shorter regimen
duration, greater likelihood of therapy completion before
TABLE 1. Recommended site-speciﬁc investigations in the evaluation and diagnostic assessment of extrapulmonary TB [32]
Site Clinical signs Imaging Biopsy Culture
Lymph node Lymph node enlargement Ultrasound Node Biopsy or aspirate
Pleura Pleural effusion Plain X-ray and computed tomography
(CT)
Pleura Biopsy
Sputum
Pleural ﬂuid
Bone/joint Involvement of weight-bearing joints (spine, hip and knee) Plain X-ray and computed tomography
(CT)
Magnetic resonance imaging (MRI)
Site of disease Biopsy
Site abscess
Joint ﬂuid
Gastrointestinal Abdominal pain
Symptoms of intestinal obstruction
Ultrasound
CT abdomen
Endoscopy
Omentum
Bowel
Biopsy
Ascites
Genitourinary Local signs and symptoms Intravenous urography
Ultrasound
Site of disease Early morning urine
Biopsy
Endometrial
curetting
Disseminated Involvement of 2 or more non-contiguous sites
Miliary TB
High-resolution CT thorax
Ultrasound abdomen
Lung
Liver
Bone marrow
Bronchial washing
Liver
Bone marrow
Blood
Central nervous
system
Meningitis
Neurological abnormalities
CT brain
MRI
Tuberculoma Biopsy
Cerebrospinal ﬂuid
Skin Ulcerative lesions
Local signs and symptoms
Site of disease Biopsy
Site abscess
Pericardium Pericardial effusion Echocardiogram Pericardium Biopsy
Pericardial ﬂuid
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transplant and potentially fewer side-effects. A less frequently
recommended regimen of rifampicin with pyrazinamide for
2 months [56] has been associated with severe liver toxicity
[57]. The choice of the agent depends on local rates of
antituberculosis drug resistance, the recipient’s country of
birth and the type of transplant [58].
Liver transplant recipients may present a high risk of
hepatotoxicity with isoniazid prophylaxis [59]. Some authors
consider that this risk outweighs any potential beneﬁts in
relation to the fairly low frequency of TB reactivation
[43,60,61] compared with the possibility of liver dysfunction
and the need for emergency transplant [36]. Other authors did
not report increased toxicity associated with isoniazid in the
liver transplant population [62–64]. In their review, Holty et al.
[65,66] reported a signiﬁcant reduction in TB reactivation and
minimal toxicity with isoniazid prophylaxis.
There is widespread agreement regarding the treatment of
LTBI in liver recipients when risk factors such as a recent
change in TST results, a history of incorrectly treated TB,
direct contact with a smear-positive TB patient, residual TB
lesions and immunosuppression factors are present
[36,43,65]. It also seems reasonable to consider treatment
only in patients with compensated cirrhosis and in whom
hepatotoxicity is closely monitored [53,67]. For the remain-
ing cases, we consider that the decision should be individ-
ualized. Other drugs such as ﬂuoroquinolones may also be
considered for LTBI treatment, although adverse effects
associated with long treatment duration have been described
[17].
Post-transplant
If the treatment of LTBI has not been conducted before
transplant, it should be performed afterwards. The indication
for and duration of isoniazid prophylaxis is the same as in the
pre-transplantation period. Universal post-transplantation iso-
niazid prophylaxis is only warranted in high endemicity areas
[68].
The interaction of isoniazid with calcineurin inhibitors is
very limited [42,69]. Isoniazid may increase corticosteroid
levels and, consequently, corticosteroid-mediated side-effects
[58]. Regimens that include rifamycins are not generally
recommended in the post-transplantation period because of
drug interactions.
Except in the case of living donors [70], clinical data
indicating whether the donor had TB may not be available.
Treatment of latent TB infection must be administered to
recipients of an organ whose donor has a history of, or data
suggesting, untreated TB [15] or recent exposure to active TB
[34], particularly in lung transplants [71]. Treatment of LTBI
should also be considered for recipients if the donor TB
screening test (TST or IGRA) was positive and the donor did
not receive chemoprophylaxis [31,68].
Recommendations for treating latent tuberculosis infection
 Treatment of LTBI should be administered to patients on
transplant waiting lists or to recipients after transplantation
who have ≥1 of the following conditions: (i) a TST (initial or
after a booster effect) with a 5-mm induration or positive
IGRA result; (ii) a history of untreated TB; or (iii) a history of
contact with a patient with active TB (AII).
 The drug of choice for LTBI is isoniazid (300 mg/day)
supplemented with vitamin B6 for 9 months (AI).
 Alternatives to isoniazid include rifampicin for 4 months
only in the pre-transplantation period (BII).
 Therapy for LTBI must be suspended if AST or ALT values
increase three-fold in patients with symptoms or ﬁve-fold in
patients without accompanying symptoms (BII).
 When isoniazid is suspended, LTBI treatment should be
completed with drugs other than isoniazid for patients with
a high risk of TB, such as those whose TST result has
recently become positive or some high-risk lung transplant
patients. Treatment with levoﬂoxacin or moxiﬂoxacin for at
least 6 months may be an option (CIII).
 Liver transplant recipients: treatment before transplantation
should be considered in patients with compensated cirrho-
sis, a recent change in TST, a history of incorrectly treated
TB, or direct contact with an untreated person with TB (BII).
Treatment of Active Tuberculosis
Pre-transplant
When active TB cannot be ruled out, we recommend initiation
of TB treatment with the standard three drugs. Treatment can
be completed with isoniazid alone if cultures for MTC are
negative after 8 weeks of incubation [36].
In general, patients with active TB should not undergo
transplantation. Possible exceptions are patients with
well-controlled infections and non-pulmonary SOT [36,67,72].
Post-transplant
The Guidelines of the Expert Group in Renal Transplantation
[73] recommend a standard 6-month regimen including
rifampicin for TB treatment, in accordance with the currently
available guidelines for the general population [41].
In our view, it is reasonable to use a prolonged course of
treatment in the immunosuppressed SOT population [36]. A
higher risk of death and relapse with short duration treatments
has also been reported [1,74,75]. However, there are no
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controlled trials assessing the optimal schedule and duration of
TB therapy in SOT recipients.
The ideal length of therapy remains controversial. Decisions
regarding the duration and the type of drugs to be used,
especially if rifampicin is not administered, are based on case
series, general population guidelines and expert recommen-
dations.
Recommendations for treating active TB in transplant
recipients also differ from those applied to the general
population, because of the interactions between rifamycins
and immunosuppressants mentioned above, and the potential
for hepatotoxicity associated with ﬁrst-line TB therapy [36].
Additionally, many ﬁrst-line anti-TB drugs (isoniazid, strepto-
mycin and ethambutol) warrant dose adjustment in renal
transplant patients.
The use of rifamycins remains controversial. The interaction
between rifampicin and calcineurin inhibitors, inhibitors of the
mammalian target of rapamycin (mTOR) and corticosteroids is
known to increase the risk of acute rejection [76–80]. The use
of rifampin has been identiﬁed as a risk factor for immune
reconstitution syndrome (IRS) related to changes in immuno-
suppressive treatment [18]. However, studies in populations
other than SOT recipients have shown an increased risk of TB
recurrence and high TB resistance rates when rifamycin-spar-
ing regimens are used [41,81].
Some authors have reported difﬁculties adjusting immu-
nosuppressive drug serum levels and a high graft failure rate
with rifampicin usage [82–84]. However, recent series have
observed no difference in post-tuberculosis rejection rate
or mortality between patients who did or did not
receive rifampicin-based regimens [2,85]. Other series
have also demonstrated that these drugs may be safe
with rigorous control of immunosuppressive drug levels
[8,74,86].
Rifabutin may be an alternative, as it appears to be as
efﬁcacious as rifampicin in HIV patients and has shown fewer
interactions with immunosuppressive drugs [36]. Favourable
experiences with rifabutin have been described in small series
of kidney and lung transplant patients [87–89]. However, other
authors have reported a similar need to increase immunosup-
pressive drug doses for rifabutin in liver transplant patients
[65].
Therefore, the beneﬁts of rifamycins must be balanced
against the risk of rejection. Their recommendation for
patients with severe or disseminated forms of tuberculosis
or with suspicion of resistance to isoniazid seems reasonable.
On the other hand, for localized, non-severe forms of
tuberculosis and transplantation periods with a high rejection
rate, physicians may weigh up the risks and beneﬁts before
including rifamycins in the anti-TB regimen.
If rifampin use is mandatory, the dose of calcineurin
inhibitors and mTOR should be increased between three-
and ﬁve-fold (increasing the frequency of administration from
twice to three times daily) and the corticosteroid dose should
be doubled [1,15,71,76,90–92]. Levels of immunosuppressants
should be closely monitored for both kinds of rifamycins and
their dose may need to be increased even in the case of
rifabutin.
Regimens including rifamycins
If the anti-TB regimen chosen includes rifampicin or rifabutin, a
standard treatment based on a three-drug regimen (with the
exception of high rates of isoniazid-resistant TB countries) may
be considered. We recommend completing treatment with
isoniazid and rifampicin or rifabutin in the maintenance phase
for at least 9 months [36].
The administration of treatment for less than 9 months has
been associated with an increased mortality rate [1]. In
addition, it has been shown that a 9–12 month period of
anti-tuberculosis treatment reduces the risk of recurrence or
treatment failure rates [74,75].
As the standard regimen of isoniazid, rifampin and pyrazin-
amide may cause signiﬁcant hepatotoxicity [1,41,75,93,94],
monitoring of the liver enzyme is mandatory. The development
of liver toxicity is of particular concern for liver transplant
patients [1,94]. Although some short series have reported
good outcomes [75,86], the standard three-drug regimen has
been more frequently associated with high percentages of
histologically conﬁrmed hepatotoxicity [95]. Alternatively,
pyrazinamide could be replaced with a ﬂuoroquinolone.
Some authors suggest that extrapulmonary TB presenta-
tions and patients with cavitary pulmonary TB who remain
culture-positive after 2 months require 12–18 months of
treatment [34,36,66,67,86].
Regimens that do not include rifamycins
Because of the interactions of transplant drugs with rifamycins,
many clinicians opt to avoid these medications if alternative
regimens are feasible. If rifampicin therapy is not used,
prolonged treatment has been considered for SOT patients
due to the experience gained in the general population.
Regimens should be continued for at least 12–18 months [15].
In rifamycin-free treatment regimens, some authors rec-
ommend a combination therapy with isoniazid and ethambutol
for 18 months with the addition of pyrazinamide for the ﬁrst
2 months [71]. In our view, maintenance agents may include
isoniazid and pyrazinamide or ethambutol, and the possible
addition of levoﬂoxacin/moxiﬂoxacin should be considered; a
three-drug regimen may reduce the treatment length [36].
Some studies have reported favourable experiences with the
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use of isoniazid, pyrazinamide and ethambutol for the ﬁrst
2 months, followed by a 12- to 18-month course of complete
therapy [74,96].
In the general population, isoniazid, pyrazinamide and
streptomycin have proven to be effective when the regimen
is administered for 9 months [41], although it is difﬁcult to
maintain injected therapy for long periods because of the risk
of ototoxicity and renal toxicity. Little information in the
transplant setting is available [97].
Fluoroquinolones (FQs) are an alternative for transplant
patients because of the disadvantages associated with rifamyc-
ins and aminoglycosides [98]. They can be used as ﬁrst-line
agents [41]. In the transplant setting, good outcomes with FQs
in the initial four-drug regimen for kidney and lung transplant
recipients have been described [11,99,100].
Current clinical trials are in progress to test the effectiveness
of 4-month FQ-containing regimens in the general population.
The preliminary results of two of these studies, the RIFAQUIN
trial (moxiﬂoxacin and rifapentine twice weekly in place of
rifampicin and isoniazid) [101] and the OFLOTUB trial (gati-
ﬂoxacin instead of ethambutol), showed the inferiority of
4-month TB regimens for outcome [102]. In addition, the
possibility that the widespread use of FQs for other infections
could lead to a high prevalence of FQ-resistant TB is amatter for
concern [103]. Other studies suggest that the prevalence of
FQ-resistant TB is still low [104].
Prolonged use of ﬂuoroquinolones may be associated with
arthralgias [17]; it may enhance the risk of tendon-related
side-effects of corticosteroids, and a combination may
decrease mycophenolate levels. An additional effect of levo-
ﬂoxacin is to increase cyclosporine levels [58] and its
combination with pyrazinamide is associated with poor
digestive tolerance [105].
Linezolid has proven to be effective for patients with TB
[106]. However, prolonged use of this drug has been
associated with thrombopenia, anaemia and polyneuropathy,
especially in patients with diabetes or kidney disease.
Recommendations for treating active tuberculosis
 For localized, non-severe forms of TB and periods with high
rejection rates, it may be advisable to avoid the use of
rifamycins (B-II).
 For severe forms of or disseminated TB, the use of a TB
regimen that includes rifampicin or rifabutin should be
considered (B-II).
 When rifamycins are used, levels of immunosuppressive
drugs should be closely monitored, and the dose of
calcineurin inhibitors, mTOR and corticosteroids should
be increased (A-II).
 In regimens that include rifamycins, maintenance therapy
with isoniazid and rifampicin or rifabutin is recommended
for at least 9 months (B-III).
 In regimens that do not include rifamycins, maintenance
therapy with isoniazid and ethambutol (or pyrazinamide) is
recommended for 12–18 months (C-III); the incorporation
of a third drug, such as pyrazinamide or levoﬂoxacin, could
reduce this period to 12 months (C-III).
Drug-resistant Tuberculosis
Multidrug-resistant (MDR) TB is deﬁned as resistance to both
isoniazid and rifampin and extremely drug-resistant (XDR) TB
is deﬁned as resistance to isoniazid, rifampin, ﬂuoroquinolones
and at least one injectable drug (i.e. amikacin, kanamycin and
capreomycin) [107].
Drug-resistant TB is not a major health problem in Western
Europe at present. However, the ﬁnding of substantial
MDR-TB among isolates from previously treated patients,
combined with the evidence that immigrants from areas where
isoniazid resistance is endemic contribute substantially to the
number of new TB cases every year, strongly suggests that
public health action is needed to improve treatment outcomes
[108]. The situation in Eastern Europe is more worrying, as
this is one of the areas with the highest proportions of TB
patients with MDR-TB in the world [7].
Only a few case reports of MDR-TB in SOT recipients have
been published [109–111]. In non-SOT individuals with
MDR-TB infection, treatment with second-line anti-TB therapy
for 18–24 months achieved a 75% long-term success rate
[112]. If isoniazid and rifamycins cannot be used, induction
treatment should include four to six drugs, including injectable
antimicrobials (e.g. streptomycin, amikacin, kanamycin or
capreomycin), linezolid or other second-line drugs, for a
prolonged period of time and should be managed only in
consultation with an infectious diseases specialist [36,67].
Although evidence is lacking, the recommended treatment
duration for these regimens is up to 2 years following MTC
culture conversion [113].
Non-Tuberculous Mycobacteria (NTM)
Introduction
Non-tuberculous mycobacteria (NTM) are ubiquitous envi-
ronmental organisms commonly found in soil and water,
whose human-to-human transmission has never been demon-
strated [114]. In SOT recipients, the incidence of NTM
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infections is much higher than in the general population due to
impaired cell-mediated immunity.
The incidence ranges between 0.16% and 0.38% in kidney
transplant recipients and is higher in heart and lung transplants
(0.24–2.8 and 0.46–2.3, respectively). The data available on
liver transplants are limited and show an incidence of 0.04%,
which may reﬂect local epidemiology, misdiagnosis or a
genuine reduced susceptibility of liver transplant recipients
to NTM infections [115–118].
With the exception of lung transplant recipients, in whom
pleuropulmonary NTM disease is the predominant manifesta-
tion, the majority of SOT patients develop cutaneous lesions of
the extremities, tenosynovitis and arthritis. Over half of these
patients exhibit disseminated involvement of non-contiguous
areas [115–118].
Diagnosis
Diagnosis of NTM infection. Pulmonary infection with NTM is
more frequent in individuals with a pre-existing condition of
impaired lung function, which provides a favourable environ-
ment for colonization and subsequent invasive disease [114].
Unfortunately, these conditions (pneumoconiosis, COPD,
cystic ﬁbrosis (CF) and bronchiectasis) are the leading
indications for receipt of a lung transplant. SOT recipients
going into surgery colonized with NTM, such as end-stage CF
patients with severe bronchiectasis [119], may develop
post-transplant infection, and around half of them undergo
host vs. graft reaction at the time of diagnosis.
Transmission of NTM infection by the transplanted organ,
though rare, has also been reported.
Recommendations for diagnosing NTM infection.
 The recognition of NTM as lung pathogens may be
under-appreciated in CF patients whose airways are chron-
ically infected with Gram-negative bacteria, as the latter may
conceal the presence of mycobacteria for a long time [119]
(BIII).
 In CF patients, a proactive pre-transplant surveillance for
respiratory NTM is recommended (AII).
Diagnosis of NTM disease. In SOT recipients, due to the effects
of immunosuppressive therapy on cell-mediated immunity,
NTM infections, though uncommon, are much more frequent
than in the general population. NTM infections generally occur
late, up to 10 years after transplantation, and the causative
agents vary depending on the type of transplant. To date, at
least 20 different species have been implicated in these
infections (Table 2). The clinical relevance of NTM may differ
according to species including organisms with a higher rate of
pathogenicity (M. kansasii, M. xenopi, M. szulgai, and M. malmo-
ense) and others with a lower rate (M. fortuitum, M. peregri-
num) [115,116,118]. Although infections caused by NTM can
increase morbidity and possibly mortality in SOT recipients,
the criteria for ﬁrm diagnosis may be uncertain and may vary
according to the site involved.
Recommendations for diagnosing NTM disease.
 Isolation of an NTM organism from a normally sterile body
site (blood, cerebrospinal ﬂuid and other sterile ﬂuids)
provides conclusive proof of invasive disease (AII).
 Local disease is fully explained when skin, soft tissue and
lymph node lesions showing granulomata on biopsy yield an
NTM species on culture (AII).
 The diagnosis of signiﬁcant pulmonary infection is more
difﬁcult because of the ubiquitous nature of the organisms
(AII).
 According to the American Thoracic Society [114], diagnosis
of signiﬁcant pulmonary infection is ﬁrmly established when
all the following criteria are fulﬁlled: (i) a compatible clinical
presentation; (ii) radiographic images consistent with the
diagnosis of NTM; (iii) exclusion of other diagnoses; and (iv)
the NTM species was either recovered from respiratory
specimens (one bronchoalveolar lavage or two consecutive
sputa) or was cultivated from pulmonary tissue (AII).
 Although the above criteria have been developed for
immunocompetent individuals with respiratory isolates of
M. avium complex, they are also believed to provide a useful
guide for assessing whether an isolate may be clinically
signiﬁcant in SOT recipients (BIII).
 Failure to respond to standard antimicrobial therapy may
provide the ﬁrst clue that the organism is unusual (BIII).
 A high index of suspicion combined with invasive procedures
and prompt transfer to the laboratory of relevant clinical
TABLE 2. Non-tuberculous mycobacteria species involved as
cause of infection in solid organ transplant recipients
Slowly growing mycobacteria Fast growing mycobacteria
M. asiaticum M. abscessus
M. avium M. bolletti
M. celatum M. chelonae
M. genavense M. fortuitum
M. haemophilum M. mageritense
M. intracellulare M. massiliense
M. gastri M. mucogenicum
M. gordonae M. neoaurum
M. kansasii
M. malmoense
M. marinum
M. scrofulaceum
M. szulgai
M. terrae
M. thermoresistibile
M. triplex
M. xenopi
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specimens are essential for rapid and accurate diagnosis
[115,116,118] (AIII).
 Clinical specimens must be cultured on both solid and liquid
media and all joint ﬂuid, skin and bone specimens incubated
at 35°C and 30°C (range 28–32°C) [38] (AII).
 If the clinical information suggests the presence of M. hae-
mophilum, M. genavense or other fastidious NTM species,
the laboratory should be promptly alerted (AII).
 Species identiﬁcation is essential for choosing effective therapy
and deciding whether DST may be performed [37] (AII).
 The correlation between in-vitro DST and the clinical
outcome has been demonstrated for a limited number of
species [114] (AII).
Prevention
Lung transplant. Non-tuberculous mycobacteria colonization
has been described as a risk factor for NTM disease and it has
been associated with an increased risk of mortality indepen-
dent of bronchiolitis obliterans syndrome [120]. As M. absces-
sus disease is difﬁcult to cure, the prevalence of M. abscessus in
colonized patients with cystic ﬁbrosis or chronic lung diseases
who may become transplant candidates is a matter of
particular concern. Some guidelines recommend that patients
with cystic ﬁbrosis colonized with rapidly growing mycobac-
teria (RGM) should be considered for post-transplant chemo-
prophylaxis to prevent surgical site infections; in addition,
patients infected or colonized with M. avium complex (MAC)
should be considered for multidrug MAC therapy prior to lung
transplantation [121].
Treatment
Non-tuberculous mycobacteria therapy is a challenge,
because NTM are inherently resistant to the majority of
ﬁrst-line tuberculostatic therapies; in addition, there are
major secondary effects with the active drugs as well as
interactions with immunosuppressive drugs. What is more,
controversy exists regarding the clinical utility of susceptibil-
ity testing. The correlation between in vitro data and clinical
outcome has been demonstrated for a limited number of
species. It is generally recommended for all species of RGM
[122].
Because the development of resistance is a regular problem,
therapy based on at least two or three active agents, including
one injectable drug, is recommended for patients with severe
infection. In general, treatment of NTM disease may require a
combination of antimicrobial therapy, surgical excision and/or
the reduction of immunosuppressive drugs [117].
The optimal duration of therapy in SOT recipients is not
known. Pulmonary disease due to NTM should usually be
treated until sputum cultures obtained over 12 consecutive
months are negative. Skin and soft tissue infections require at
least 3–6 months [123]. No data are available for disseminated
NTM infection. Close clinical follow-up after discontinuation of
antimicrobial agents is important in all cases. The recom-
mended drugs for treating the most common NTM infections
are listed in Tables 3 and 4.
Recommendations for treating NTM disease.
 NTM disease usually requires antimicrobial therapy, surgical
excision and/or the lessening of immunosuppressive drugs
(BIII).
 Therapy should be started with at least two active agents
due to the high risk of development of resistance (BIII).
 A life-threatening illness or high infectious burden should be
treated with three or more active drugs (BIII).
TABLE 3. Recommended drugs for slow-growing non-tuber-
culous mycobacteria (NTM) species involved in solid organ
transplant (SOT) recipient infections [117]
NTM species
First-line
treatment
Second-line
drugs
Validated
DSTa
M. avium
complex
Azithromycin
Rifabutin
Ethambutol
Rifampicin
Clarithromycin
Amikacin
Moxiﬂoxacin
Clarithromycin
M. kansaii Rifabutin
Ethambutol
Isoniazid
Rifampicin
Clarithromycin
Azithromycin
Amikacin
Moxiﬂoxacin
Sulfamethoxazole
Rifampicin
M. marinum Azithromycin
Ethambutol
Rifampicin
Rifabutin
Clarithromycin
Cotrimoxazole
Doxycicline
Sulfonamides
Rifampicin
Ethambutol
aDrugs for which a correlation between in-vitro results and clinical outcome has
been demonstrated.
TABLE 4. Recommended drugs for fast-growing non-tuber-
culous mycobacteria (NTM) species involved in solid organ
transplant (SOT) recipient infections [117]
NTM
species
First-line
treatment
Second-line
drugs Validated DSTa
M. abscessus Amikacin
Clarithromycin
Cefoxitin
Imipenem
Linezolid
All ﬁrst- and
second-line drugs
M. chelonae Clarithromycin
Tobramycin
Azithromycin
Amikacin
Imipenem
Linezolid
All ﬁrst- and
second-line drugs
M. fortuitum Ciproﬂoxacin
Cefoxitin
Clarithromycin
Azithromycin
Imipenem
Amikacin
Moxiﬂoxacin
Doxycicline
Cotrimoxazole
All ﬁrst- and
second-line drugs
aDrugs for which a correlation between in-vitro results and clinical outcome has
been demonstrated.
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